Next-Gen analytics for mRNA and LNPs: when traditional methods fall short

Following the first mRNA-LNP based Covid-19 vaccines, a plethora of new modalities were invented that are directed to treating and preventing diseases in previously unimaginable ways. With these new modalities, both in the field of XNA and their encapsulating modalities (Lipid Nano Particles) standard methods fall short, lacking the resolution, specificity, and adaptability needed to characterize these advanced molecules. In this webinar, we’ll uncover the hidden challenges in analyzing next-generation RNA and LNP therapies, and explore how Lonza is pioneering advanced, fit-for-purpose analytics to meet the demands of this fast-moving field.